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Background: Tunnelled central venous dialysis catheter use is significantly limited by the occurrence of
catheter-related infections. This randomised controlled trial assessed the efficacy of a 48 hour 70% ethanol lock vs
heparin locks in prolonging the time to the first episode of catheter related blood stream infection (CRBSI).
Methods: Patients undergoing haemodialysis (HD) via a tunnelled catheter were randomised 1:1 to once per week
ethanol locks (with two heparin locks between other dialysis sessions) vs thrice per week heparin locks.
Results: Observed catheter days in the heparin (n=24) and ethanol (n=25) groups were 1814 and 3614 respectively.
CRBSI occurred at a rate of 0.85 vs. 0.28 per 1000 catheter days in the heparin vs ethanol group by intention to
treat analysis (incident rate ratio (IRR) for ethanol vs. heparin 0.17; 95%CI 0.02-1.63; p=0.12). Flow issues requiring
catheter removal occurred at a rate of 1.6 vs 1.4 per 1000 catheter days in the heparin and ethanol groups
respectively (IRR 0.85; 95% CI 0.20-3.5 p =0.82 (for ethanol vs heparin).
Conclusions: Catheter survival and catheter-related blood stream infection were not significantly different but there
was a trend towards a reduced rate of infection in the ethanol group. This study establishes proof of concept and
will inform an adequately powered multicentre trial to definitively examine the efficacy and safety of ethanol locks
as an alternative to current therapies used in the prevention of catheter-associated blood stream infections in
patients dialysing with tunnelled catheters.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12609000493246
Keywords: Catheter related blood stream infection (CRBSI), Central venous catheter, Ethanol, Lock therapy,
Haemodialysis (HD), ProphylaxisBackground
Catheter associated infection is a difficult clinical prob-
lem in renal medicine with blood stream infections
occurring in up to 40% of patients with haemodialysis
catheters, conferring significant rates of morbidity and
mortality [1,2]. Methods to reduce rates of infection in-
clude intraluminal and extraluminal approaches. Extra-
luminal methods include topical antimicrobial dressings
at the catheter exit site [3], and tunnelling of the catheter* Correspondence: jennifer_broom@health.qld.gov.au
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reproduction in any medium, provided the or[4]. Catheter lock solutions and coating catheters with
antimicrobial substances [5] address intraluminal sources
of infection. Prophylactic lock solutions that have been
studied include antibiotic locks and sodium citrate locks
[6,7]. Consensus within the literature about the efficacy
of different lock solutions is limited because the method-
ology of trials reported is often poor, with frequent use of
historical controls, or reports in the form of case series
with no control group. In addition, there is variation be-
tween trials in the concentrations, and length of dwell
time with each type of lock study, and these variations
in combination with often disparate patient groups and
diverse catheter types make conclusions from the limitedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the use of antibiotic lock solutions include the potential
for the development of bacterial resistance [8], limited
efficacy, and toxicity from blood stream levels of lock
antibiotics, such as gentamicin [9]. Moreover, sodium
citrate locks were shown in a recent randomised con-
trolled trial to provide no significant protection against
catheter-associated infection and to increase the risk
of catheter thrombosis [6]. Ethanol is attractive as a
prophylactic lock solution as it is bactericidal by protein
denaturation, has a broad range of antimicrobial activity
[10], is relatively inexpensive, is metabolised by humans,
and does not damage catheters by prolonged exposure
[11,12].
To date, there have only been a small number of
studies examining the clinical utility of prophylactic
ethanol lock therapy, although these have been limited
by small numbers, short-follow-up durations, absence of
controls or use of historical controls, failure to evaluate
dialysis patients and conflicting findings [13-18].
The aim of the present study was to prospectively
determine whether a 48 hour ethanol lock was a practical
and effective strategy for reducing catheter-associated
blood stream infections and prolonging the life of the
tunnelled catheter in HD patients. Ethanol lock-related
complications were also evaluated.Methods
This study protocol has been published elsewhere [19].
A prospective open-label randomised controlled trial
design was used to allocate adult patients dialysing
through a tunnelled central venous catheter 1:1 to receive
3mL of intravenous grade 70% ethanol into each lumen
of the catheter once per week and standard heparin locks
for other dialysis days, or to receive heparin locks only.
The primary outcome measure was time to the first epi-
sode of CRBSI. Secondary outcomes included incidence
of CRBSI caused by different pathogens, time to exit site
infection, time to infection-related catheter removal, time
to catheter removal and adverse reactions.
A flow diagram demonstrating patient recruitment
and flow throughout the trial is shown (Figure 1). Ethical
approval for the trial was obtained from the Princess
Alexandra Human Research Ethics Committee. Partici-
pants were selected from patients undergoing HD at the
Princess Alexandra Hospital, Logan Hospital, and Red-
land Hospital in Brisbane, Queensland, with prevalent
and incident tunnelled catheters in the internal jugular
vein. Inclusion criteria were; adults > 18 years, the pre-
sence of a tunnelled intravenous catheter and the ability
to give informed consent. Exclusion criteria included
pregnancy or breast feeding, religious or personal objec-
tion to the use of ethanol, intolerance of ethanol, and ahistory of an exit site, tunnel or blood stream infection
associated with the current catheter.
The study was a prospective, open-label, randomised,
controlled trial. Both incident catheters (recruitment for
the trial at catheter insertion) and prevalent catheters
(recruited to the trial with a previously inserted catheter)
were entered into the trial. Incident and prevalent
catheters were stratified prior to randomisation. The
trial design was not blinded as the odour of ethanol
can be discerned by patients and staff during administra-
tion which would compromise the blinding. Adequate
allocation concealment was ensured using a centralised
computer generated block randomisation procedure.
Randomisation occurred on the day that trial consent
was obtained and was conducted by calling a centralised
number to allocate the patient to a trial arm. Participants
were randomly allocated to receive either thrice weekly
standard heparin locks (Heparin sodium 5000 U/mL,
Hospira, Germany) (control group) or weekly catheter
instillation of 3 mL intravenous-grade 70% ethanol for
48 hours together with standard heparin locks (ethanol
group) following the remaining 2 HD sessions each
week. Ethanol 99% (dehydrated alcohol USP injection,
Phebra Pty Ltd, NSW 2066, Australia) was diluted to
70% with sterile water for injections BP (AstraZenica
Pty Ltd, 2–6 Alma Road, North Ryde, NSW, 2113) with
the addition of 7mL ethanol to 3mL water (total 10mL,
3 mL of which was instilled in each lumen) in a syringe
by the nurses on the haemodialysis unit. The locking
agents were instilled into each lumen of the catheter at
the end of a HD session and left in situ until the next
dialysis session when they were aspirated. Ethanol locks
were not administered more frequently than once per
week due to concerns about the risk of catheter throm-
bosis caused by a reduction in heparin lock dwell time.
Patients in each trial arm received catheter care as
per the local haemodialysis unit protocol which included
the following; cleansing the catheter site and changing
of dressing at each use: existing dressing removed and
alcoholic chlorhexidine 70% used to cleanse site;
Medihoney TM Antibacterial Wound Gel TM applied
around catheter exit site ; new Tegaderm TM I.V. Trans-
parent Dressing applied. Patients with suspected CRBSI
(assessed clinically as the presence of fever or other signs
of sepsis in a patient with an indwelling central venous
catheter, with no alternative source of infection identified)
were investigated with blood cultures drawn from per-
ipheral veins and from catheter lumens, removal of the
catheter with tip culture, and empirical systemic anti-
biotic administration: Dicloxacillin 1 gram or Cefazolin
1 gram (if non-severe penicillin allergy) or Vancomycin
1 gram (if severe penicillin allergy or if known MRSA
carrier) and Gentamicin 2–3 mg/kg. The primary out-
come measure was time to the first episode of CRBSI.
Patient Population
Inclusion: 
-incident or prevalent HD patients with tunnelled intravenous catheters
-able to give informed consent
Exclusion:
-intolerance to ethanol
-personal, cultural or other objection to the use of ethanol
-history of an exit site, tunnel, or bloodstream infection associated with the current catheter
-Pregnancy
Ethanol lock
3mL 70% lock weekly after HD











time to first episode of catheter-related blood stream infection (CRBSI)
Secondary Endpoints – whether intervention results in: 
•adverse reactions
•incidence of CRB caused by different pathogens
•time to infection-related catheter removal
•time to exit site infection 
Randomisation
Stratification
-Incident catheters n=15 
-prevalent catheters n=34




Allocated to ethanol locks n= 25  
Received ethanol locks n=  25 
Did not receive ethanol locks n= 0    
Allocated to heparin locks n=24     
Received heparin locks n=  24  
Did not receive heparin locks n=0     
Lost to follow-up n=0
Discontinued ethanol locks prior to catheter removal 
n=9
Lost to follow-up n=0
Discontinued heparin locks prior to catheter removal 
n=0
[Removal from the trial did not result in heparin 
lock cessation if the catheter remained in situ as 
heparin locks are the standard of care for prevention 
of catheter thrombosis in this unit.  Follow-up of 
outcomes still occurred]
Analysed  n= 25
Excluded from analysis n=0 Analysed  n= 24
Excluded from analysis n=0
Figure 1 Patient recruitment, stratification, randomisation and analysis in the HEALTHYCATH Trial is represented in a flow diagram.
Broom et al. BMC Nephrology 2012, 13:146 Page 3 of 9
http://www.biomedcentral.com/1471-2369/13/146
Table 1 Patient characteristics in ethanol lock and






-→Male 13 (52%) 11 (46%)
-→Female 12 (48%) 13 (54%)
Age (years, mean±SD) 52±18 64±16
Duration of current catheter use prior
to trial entry (median days)
25 18.5
Aetiology of chronic kidney disease
-→Diabetic nephropathy 8 (32%) 6 (25%)
-→Glomerulonephritis 8 (32%) 7 (29%)
-→Polycystic kidney disease 2 (8%) 2 (8%)
-→Hypertension 1 (4%) 3 (13%)
-→Chronic interstitial nephritis 1 (4%) 1 (4%)
-→Analgesic nephropathy 1 (4%) 1 (4%)
-→Other 4 (16%) 4 (16%)
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Kidney Disease Outcomes Initiative (KDOQI) definitions
(Vascular Access 2006 Work Group. Clinical practice
guidelines for vascular access. Am J Kidney Dis 2006;48
(Suppl 1): S176–S247). Exit-site infection was defined as
inflammation confined to the area surrounding the ca-
theter exit site, not extending superiorly beyond the cuff,
with excudate culture confirmed to be positive. Tunnel
infection was defined as pain and inflammation of the
tunnel superior to the cuff which may also have drainage
of pus from the exit site that was culture positive.
Catheter-related blood stream infection (CRBSI) was
defined as positive blood cultures for the presence of
bacteria with or without accompanying fever. Definite
CRBSI required the same organism from a semiquantita-
tive culture of the catheter tip (>15 colony-forming units
per catheter segment) and from a peripheral or catheter
blood sample in a symptomatic patient with no other
apparent source of infection. Probable CRBSI required
defervescence of symptoms after antibiotic therapy in
the setting in which blood cultures confirmed infection,
but catheter tip did not in a patient with no other
apparent source of infection. Possible CRBSI required
defervescence of symptoms after antibiotic treatment or
after removal of catheter in the absence of laboratory
confirmation of bloodstream infection in a symptomatic
patient with no other apparent source of infection. Se-
condary outcomes included incidence of CRBSI caused
by different pathogens, time to exit site infection, time
to infection-related catheter removal, time to catheter
removal and adverse reactions. Flow problems were
defined as catheter blockage or reduced flow rates that
required catheter removal (failing to respond to thrombo-
lytic therapy) or precipitated removal from the trial.
Mechanical dysfunction was any dysfunction of the
catheter such as a split, but not including catheter
blockage, which required catheter removal. Patients were
followed until the removal of the central venous catheter.
Statistical analysis
Results were expressed as number (%) for categorical
data, mean ± standard deviation for continuous normally
distributed data and median [interquartile range] for
continuous data that was not normally distributed. Count
data were described as the number of events observed,
the mean/1000 catheter days and the 95% confidence
intervals for the estimation of the mean. Kaplan-Meier
plots were used to analyse catheter survival and the log
rank test was used to examine the statistical differences
in the survival curves. The incidence of adverse events
was compared between the 2 groups using negative bino-
mial regression. Results of negative binomial regression
analyses were reported as incidence rate ratio (IRR) and
95% confidence interval (CI) with a p value testing thenull hypothesis: IRR=1. Prospective power calculations
indicated that the study would have adequate statistical
power (80% probability) to detect a clinically signifi-
cant increase in infection-free survival from 200 days
to 400 days if 56 patients were recruited into each arm
(total 112 patients). These assumptions were based on
local data in HD patients at the Princess Alexandra
Hospital. A recruitment period of 3 years was anticipated
based on rates of tunnelled central venous catheter
dialysis at the initiation of the study. All analyses were
carried out using Graphpad Prism version 5 software
and Stata SE version 11.0. All data were analysed on
an intention-to-treat basis. P values < 0.05 were con-
sidered significant.Results
Participants
Of a planned 112 participants, 49 patients were recruited
from October 2006 to November 2010 (Figure 1). Access
to fistula formation and peritoneal catheter insertion at
the Princess Alexandra Hospital improved dramatically
during the study period, thereby markedly reducing the
rate of recruitment to the study. During the study,
annual PD Tenckhoff catheter insertion rates increased
by approximately 40%, whilst prevalent HD catheter rates
fell from in excess of 30% to 3% by the end of the study.
A decision was therefore made to close the trial before the
planned recruitment had been completed. Of 49 patients,
25 were randomised to the ethanol lock arm of the trial
and 24 to the heparin lock arm. There were no signifi-
cant differences in age, gender, or aetiology of chronic
kidney disease between the two groups (Table 1).
Table 2 Outcomes of the trial for ethanol lock and heparin lock arms are shown
Variable Ethanol lock Heparin lock IRR (95% CI );
p value(/1000 catheter days; 95%CI) (/1000 catheter days; 95%CI)
Total observation period from trial entry (days) 3614 1834
Total Complications (intention to treat):
infective and non-infective
9 (2.5; 95% 8 (4.4; 95% 0.57 (0.22-1.5);
CI 1.1-4.7) CI 1.9-8.6) p = 0.25
Non-infective 7 (1.9; 95% 4 (2.2; 95% 0.88 (0.26- 3.0);
CI 0.78-4.0) CI 0.59-5.6) p=0.85
-→Flow difficulties 5 (1.4; 95% 3 (1.6; 95% 0.85 (0.20-3.5);
CI 0.45-3.2) CI 0.32-4.8) p=0.82
-→Thrombosis 0 0
-→Mechanical dysfunction 2 1
Infective 2* (0.55; 95% 4 (2.2; 95% 0.25 (0.05-1.4);
CI 0.067-2.0) CI 0.59-5.6) p=0.113
-→CA-BSI - definite or probable¥ 1 (0.28; 95% 3 (0.85; 95% 0.17 (0.02-1.63);
CI.00-1.5) CI 0.20-3.5) p=0.12
-→CA-BSI suspected 0 1
-→Exit site infection 1 0
-→Tunnel infection 0 0
* This number represents all infectious complications on an intention-to-treat basis. One CA-BSI occurred in a catheter after exit from the trial in the ethanol arm.
Therefore, in Table 4, the infectious complications resulting in trial exit are listed as 1 because the second infection occurred after trial exit.
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A total of 3614 catheter days were observed in the
ethanol lock arm and 1834 catheter days in the heparin
lock arm from trial entry (Table 2). The intended primary
outcome analysis, time to catheter association blood
stream infection, definite or probable is shown in
Figure 1. There were only 3 events in the heparin group
and 1 event in the ethanol group for this outcome.
Applying tests to assess differences in time to event wasFigure 2 Kaplan-Meier infection-free survival curves for the heparin a
numbers at risk at each time point are shown below the abscissa.not appropriate with the numbers observed. Numerous
censoring events occurred (Figure 2); the main reason
being that the catheters were no longer required as per-
manent access was able to be accessed.Catheter complications (non infective)
Catheter complications resulting in removal of the
catheter occurred in the ethanol vs heparin groups atnd ethanol groups. Censoring events are indicated in the graph. The
Table 3 Causative pathogens for catheter-related blood stream infections occurring during the trial
Code Lock solution Days on trial Organism isolated Isolated from
2 Heparin 78 Staphylococcus aureus Blood culture 1 set, catheter tip
>100 colony forming units (cfu)
24 Heparin 134 Enterobacter cloacae Blood culture - 1 set
27 Heparin 135 Staphylococcus hominis Blood culture - 2 sets, 2 days apart
35 Ethanol 51 (infection occurred 303 days
later after trial exit)
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events per 1000 catheter days. Comparing these rates,
the incident rate ratio (IRR) for ethanol compared with
heparin was 0.88 (95% CI 0.26 – 3.0; p = 0.85. Of these
complications, flow difficulties were the most frequent
event observed. The rates were 1.4 (95% CI 0.45-3.2) vs
1.6 (95% CI 0.32-4.8) per 1,000 catheter days for ethanol
vs heparin groups respectively, IRR 0.85 (95% CI 0.20-
3.5; p =0.82).
Catheter-related infections
Catheter-related blood stream infections (defined as
probable and definite CR-BSIs) occurred on intention to
treat analysis in ethanol vs heparin arms at rates of 0.28
(95% CI 0.00-1.5) vs 0.85 (95% CI 0.20-3.5) per 1000
catheter days (IRR 0.17; 0.02-1.63; p=0.12: Table 2).
Comparing the rates of all infective events (included de-
finite or probable CR-BSIs, suspected CI-BSIs and exit
site and tunnel infections), the rates in the ethanol vs
heparin groups were 0.55 (95% CI 0.07 – 2.0) vs 2.2
(95% CI 0.59-5.6) per 1000 catheter days (IRR 0.25;
95% CI −0.05-1.4; p = 0.113).
Causative pathogens are listed (Table 3). No CR-BSI
infections occurred in the ethanol group while receiving
ethanol locks, although one infection occurred in a
patient who had previously received ethanol locks,
303 days after trial exit due to disrupted ethanol supply.
In the intention to treat analysis, this infection wasTable 4 Exit from trial and/or end of study events for ethano
Reason for exit from the trial Ethanol
Lock
Catheters removed (total) 25
Catheter no longer required 6
Infectious complications 1
Non infectious reasons for exit from trial 18*
*Split catheter (1), flow problems or blocked catheter (5), intensive care admission u
(2), not specified (1), relocation to a non trial site (1), non-compliance with trial prot
#Catheter fell out (1), flow problems or blocked catheter (3), bleeding from cathete
dialysis (1), relocation to non trial site (1).included in the ethanol arm. The organisms isolated in
the 3 patients on the heparin arm who had CR-BSI
were: Staphylococcus aureus, Enterobacter cloacae, and
Staphylococcus hominis. One patient met criteria for
definite CR-BSI (patient 2, isolating Staphylococcus aureus
from both blood cultures and catheter tip culture). The
other two patients met criteria for probable CR-BSI.
CR-BSIs occurred after 78, 134, and 135 days on the trial.
All 3 catheters were removed. One patient in the ethanol
arm acquired a definite CR-BSI in which the causative
organism was Staphylococcus aureus, cultured in blood
cultures from both the tunnelled catheter and periphe-
rally and from the catheter tip on removal. This infection
occurred 303 days after cessation of ethanol lock therapy.
One exit site infection from which methicillin resistant
Staphylococcus aureus (MRSA) was cultured from an
exit site swab occurred in the ethanol arm resulting in
removal of the catheter. No exit site infections were
documented in the heparin arm. Tunnel infections did
not occur in either arm.
Exit from trial
Reasons for patients exiting from trial are outlined in in
Table 4. Of the non-infectious reasons for removal from
the trial, four patients in the ethanol arm were removed
from the study at their own request. The first was
removed after 126 days on the trial due to a problem
aspirating an ethanol lock which required a single flushl lock and heparin lock arms are shown
Heparin
Lock
Statistical analysis (where appropriate)
IRR (95% CI ); p value
24 IRR 0.53 (0.30 -0.93)
P=0.03
12 IRR 0.25 (0.10-0.68)
P=0.006
4 See Table 2
8#
nrelated to the trial (1), patient request (4), reduced to twice weekly dialysis
ocol (1), deceased (1), ethanol supply temporarily ceased (1).
r site (1), patient non compliance with dialysis (1), reduced to twice weekly
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of stinging at the catheter exit site on administration of
the ethanol lock and was removed from the trial after
2 days. The third patient was removed from the trial at
their own request after 8 days with no documentation as
to the reason in the patient record. The fourth patient
complained of dry lips, being thirsty, and having “flow
problems”, although the flow problems were not docu-
mented by the clinical staff the patient was removed from
the trial after 15 days. No patients in the heparin arm
requested removal from the trial.
Five patients in the ethanol arm and three in the
heparin arm were removed from the trial because of flow
problems. Mechanical problems with the catheter oc-
curred once in both groups. One patient in the ethanol
arm had a split catheter, and one patient in the heparin
group had a catheter that fell out. Other non-infectious
reasons for removal from the trial for patients in the
ethanol group were; intensive care admission unrelated to
the trial (n=1), reduction to twice weekly dialysis (n=2),
relocation to a non-trial site (n=1), non-compliance with
trial locks (n=1), patient deceased (n=1), a temporary dis-
ruption to ethanol supply (n=1), and one patient that was
removed for an unspecified reason. Patients in the he-
parin group were removed from the trial because of;
bleeding from catheter site (n=1), patient non-
compliance with dialysis (n=1), reduction to twice weekly
dialysis (n-1), and relocation to a non-trial site (n=1).
Discussion
This is the first study of prophylactic ethanol lock the-
rapy in patients with end-stage kidney failure undergoing
HD via a tunnelled central catheter. Although the study
did not reach the expected recruitment targets and there-
fore the results did not reach statistical significance due
to a type 2 error, it would appear that ethanol is a safe
and potentially effective intervention in this patient
group. There was a trend towards increased catheter sur-
vival and a decreased rate of catheter-associated blood
stream infection with the use of a once per week ethanol
lock. These beneficial effects were particularly observed
in incident (newly inserted) dialysis catheters.
These findings are in keeping with those of a previous
randomised controlled trial of 64 prophylactic treatment
periods with a daily ethanol lock or placebo with a dwell
time of two hours in 60 haematology inpatients with
either tunnelled or untunnelled catheters [17]. Ethanol
lock therapy was associated with a significant reduction
in catheter-associated blood stream infections in the
ethanol arm compared to control.
On the other hand, a second much larger trial of
tunnelled catheters in 376 haematology inpatients and
outpatients [18] reported that ethanol locks (15 minute
dwell time applied daily to inpatients or weekly tooutpatients) did not result in a reduction in catheter-
associated blood stream infections compared with con-
trols. However, the rates of blood stream infections were
low (0.7 vs 1.19 per 1000 catheter days in the ethanol vs
placebo groups, p=0.19), such that the study may have
been underpowered to show an effect.
An uncontrolled trial of prophylactic ethanol locks in
paediatric patients undergoing monoclonal antibody
treatment for neuroblastoma was ceased early when 3 of
12 catheters became occluded [14]. The low numbers in
this trial and the lack of a control group limit the conclu-
sions that can be drawn, but indicate that ethanol lock
treatments should be prospectively studied and appro-
priately controlled to evaluate this complication in pae-
diatric populations.
A recent study of 90 episodes of 48 hour 60% ethanol
locks in 30 HD patients with evaluation of the pre- and
post-intervention period (each patient acting as their
own control) found a transient increase in catheter dys-
function related to ethanol lock therapy, although no
catheter required removal [20]. Each patient had a total
of only three consecutive ethanol dwell periods, such that
the effect of ethanol locking in the longer term in this
patient population was not able to be assessed.
A significant concern in designing this trial was
whether thrombotic complications would occur in the
ethanol arm as a result of the 48 hour period without a
heparin lock in situ. Flow problems did occur in both
arms with 4 of 25 (16%) ethanol lock patients experien-
cing flow related problems requiring catheter removal
compared to 3 of 24 (13%) heparin lock patients. There
was not a significant increase in catheter thrombosis
requiring catheter removal in the ethanol lock group.
Previous studies of the effects of catheter exposure to
ethanol have demonstrated that silicone dialysis catheter
integrity is maintained, as assessed by scanning electron
microscopy, even after 15 days exposure to 95% ethanol
solution [12]. The amount of silicone released was not
significantly different when the catheter was submerged
in ethanol compared to 0.9% sodium chloride. Mecha-
nical testing of polyurethane and silicone catheters
exposed to ten weeks of 70% ethanol proved ongoing
structural integrity of both catheter types after prolonged
ethanol exposure [11].
Ethanol is an antiseptic agent which is bactericidal by
protein denaturation and is active against a wide variety
of organisms including Gram-positive bacteria, Gram-
negative bacteria, and fungi. In vitro studies have been
published demonstrating the bactericidal effect of 70%
ethanol against plastic-adherent organisms that commonly
cause line infections [10]. Complete eradication of Gram-
negative bacilli, Gram-positive cocci, and Candida albi-
cans biofilms occurred with 30 minutes treatment with
60% ethanol compared to no eradication with 46.7%
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nol locks with incident catheters in the present study
might be potentially related to enhanced effectiveness in
catheters in which biofilm has not yet formed. However,
the small numbers of incident catheters in the present in-
vestigation indicate that further studies are warranted to
confirm this finding.
The principal limitations of this study were its open
label design, leading to the possibility of reporting bias,
and small patient numbers leading to the possibility of
type 2 statistical error. Although it was theoretically pos-
sible to have blinded this trial by having pharmacy make
up syringes filled with heparin or ethanol lock solutions
for each patient (as published in a previous prophylaxis
trial [17], the distinctive odour of ethanol during ca-
theter instillation would have been discerned by the
administering nurse and patient, thereby compromising
the integrity of the blinding. Another significant limita-
tion of this study is the large number of patients exiting
the trial prior to catheter removal, particularly in the
ethanol arm. The specific reasons for trial exit are
detailed in the results section. The analysis of the trial
has been performed on an intention-to-treat basis con-
sistent with CONSORT guideline recommendations
[21]. This methodology does result in a significant number
of catheter days in which treatment was not per-protocol
on the ethanol arm. The single CR-BSI that occurred in
the ethanol lock arm occurred 303 days after cessation of
ethanol lock therapy. However it is included in the ethanol
lock arm for analysis. Per-protocol analysis would address
this issue but would compromise the effect of random
allocation and therefore was not used.
Antibiotic lock solutions have been studied in the pre-
vention of catheter associated blood stream infections and
do confer a protective effect, as reported in two recent
meta-analyses [7,22]. However, the studies were limited
with respect to uniformity and long term outcome data,
and the use of long term antibiotics in a prophylaxis role
still confers the potential for the development of anti-
microbial resistance. These studies do support the use of
locking solutions, however, and alternative agents such as
ethanol could potentially allow for a protective benefit
without the risk of resistance.
Conclusions
In conclusion, although the results of this trial are not
statistically significant, the trend towards a longer catheter
life and a reduction in catheter associated blood stream
infection establishes proof of concept and warrants a
multi-centre trial to enroll larger patient numbers to fur-
ther assess the role of ethanol locks in the prevention of
catheter-associated blood stream infections in patients
dialysing via tunnelled catheters. Ethanol is an inexpen-
sive, non toxic, bactericidal agent that has potential utilityas a lock therapy in preventing catheter associated infec-
tions. This trial indicates that the intervention is safe and
acceptable to patients undergoing haemodialysis, and may
reduce CRBSI. Further multi-centre studies are required
to provide power to evaluate the efficacy in prevention of
infection. If effective, an agent that does not have an asso-
ciation with the development of antimicrobial resistance
would be highly desirable as a prophylaxis agent.
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